{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T19:27:59Z","timestamp":1791833279204,"version":"4.3.4"},"reference-count":33,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2023,3,16]],"date-time":"2023-03-16T00:00:00Z","timestamp":1678924800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Janssen Pharmaceuticals"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>RSV is divided into two antigenic subtypes, RSV A and RSV B, which is largely based on the variation in the G protein, while the fusion protein F is more conserved and a target for antibody-mediated neutralization. Here we evaluate the breadth of the protective immune responses across RSV A and RSV B subtypes, induced by vaccines based on the RSV A-based fusion protein, stabilized in the prefusion conformation (preF) in preclinical models. Immunization of na\u00efve cotton rats with preF subunit or preF encoded by a replication incompetent Adenoviral 26, induced antibodies capable of neutralizing recent RSV A and RSV B clinical isolates, as well as protective efficacy against a challenge with RSV A and RSV B strains. Similarly, induction of cross-neutralizing antibodies was observed after immunization with Ad26-encoded preF, preF protein or a mix of both (Ad26\/preF protein) in RSV pre-exposed mice and African Green Monkeys. Transfer of serum of human subjects immunized with Ad26\/preF protein into cotton rats provide protection against challenges with both RSV A and RSV B, with complete protection against both strains observed in the lower respiratory tract. In contrast, almost no protection against RSV A and B infection was observed after the transfer of a human serum pool isolated pre-vaccination. These results collectively show that the RSV A-based monovalent Ad26\/preF protein vaccine induced neutralizing antibodies, as well as protection against both RSV A and RSV B subtypes in animals, including by passive transfer of human antibodies alone, suggesting that clinical efficacy against both subtypes can be achieved.<\/jats:p>","DOI":"10.3390\/vaccines11030672","type":"journal-article","created":{"date-parts":[[2023,3,16]],"date-time":"2023-03-16T03:50:45Z","timestamp":1678938645000},"page":"672","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":21,"title":["RSV A2-Based Prefusion F Vaccine Candidates Induce RSV A and RSV B Cross Binding and Neutralizing Antibodies and Provide Protection against RSV A and RSV B Challenge in Preclinical Models"],"prefix":"10.3390","volume":"11","author":[{"given":"Freek","family":"Cox","sequence":"first","affiliation":[{"name":"Janssen Vaccines & Prevention B.V. Archimedesweg 4-6, 2333 CN Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7060-1181","authenticated-orcid":false,"given":"Eirikur","family":"Saeland","sequence":"additional","affiliation":[{"name":"Janssen Vaccines & Prevention B.V. Archimedesweg 4-6, 2333 CN Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Thoma","sequence":"additional","affiliation":[{"name":"Janssen Vaccines & Prevention B.V. Archimedesweg 4-6, 2333 CN Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-0753-8769","authenticated-orcid":false,"given":"Ward","family":"van den Hoogen","sequence":"additional","affiliation":[{"name":"Janssen Vaccines & Prevention B.V. Archimedesweg 4-6, 2333 CN Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisanne","family":"Tettero","sequence":"additional","affiliation":[{"name":"Janssen Vaccines & Prevention B.V. Archimedesweg 4-6, 2333 CN Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7847-2433","authenticated-orcid":false,"given":"Joke","family":"Drijver","sequence":"additional","affiliation":[{"name":"Janssen Vaccines & Prevention B.V. Archimedesweg 4-6, 2333 CN Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cornelis","family":"Vaneman","sequence":"additional","affiliation":[{"name":"Janssen Vaccines & Prevention B.V. Archimedesweg 4-6, 2333 CN Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yolinda","family":"van Polanen","sequence":"additional","affiliation":[{"name":"Janssen Vaccines & Prevention B.V. Archimedesweg 4-6, 2333 CN Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tina","family":"Ritschel","sequence":"additional","affiliation":[{"name":"Janssen Vaccines & Prevention B.V. Archimedesweg 4-6, 2333 CN Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arangassery Rosemary","family":"Bastian","sequence":"additional","affiliation":[{"name":"Janssen Vaccines & Prevention B.V. Archimedesweg 4-6, 2333 CN Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benoit","family":"Callendret","sequence":"additional","affiliation":[{"name":"Janssen Vaccines & Prevention B.V. Archimedesweg 4-6, 2333 CN Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2822-6231","authenticated-orcid":false,"given":"Roland","family":"Zahn","sequence":"additional","affiliation":[{"name":"Janssen Vaccines & Prevention B.V. Archimedesweg 4-6, 2333 CN Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie","family":"van der Fits","sequence":"additional","affiliation":[{"name":"Janssen Vaccines & Prevention B.V. Archimedesweg 4-6, 2333 CN Leiden, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,3,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1093\/cid\/ciy991","article-title":"Severe Morbidity and Mortality Associated with Respiratory Syncytial Virus Versus Influenza Infection in Hospitalized Older Adults","volume":"69","author":"Ackerson","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"S577","DOI":"10.1093\/infdis\/jiz059","article-title":"Global disease burden estimates of respiratory syncytial virus-associated acute respiratory infection in older adults in 2015: A systematic review and meta-analysis","volume":"222","author":"Shi","year":"2020","journal-title":"J. Infect. Dis."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1093\/infdis\/163.4.693","article-title":"Immunity to and frequency of re-infection with respiratory syncytial virus","volume":"163","author":"Hall","year":"1991","journal-title":"J. Infect. Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1093\/infdis\/jix489","article-title":"Prefusion F, Postfusion F, G Antibodies, and Disease Severity in Infants and Young Children with Acute Respiratory Syncytial Virus Infection","volume":"216","author":"Capella","year":"2017","journal-title":"J. Infect. Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"309ra162","DOI":"10.1126\/scitranslmed.aac4241","article-title":"Prefusion F-specific antibodies determine the magnitude of RSV neutralizing activity in human sera","volume":"7","author":"Ngwuta","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3089","DOI":"10.1073\/pnas.1115941109","article-title":"Neutralizing antibodies against the preactive form of respiratory syncytial virus fusion protein offer unique possibilities for clinical intervention","volume":"109","author":"Magro","year":"2012","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.coi.2015.04.005","article-title":"Novel antigens for RSV vaccines","volume":"35","author":"Graham","year":"2015","journal-title":"Curr. Opin. Immunol."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Biagi, C., Dondi, A., Scarpini, S., Rocca, A., Vandini, S., Poletti, G., and Lanari, M. (2020). Current state and challenges in developing respiratory syncytial virus vaccines. Vaccines, 8.","DOI":"10.3390\/vaccines8040672"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1093\/infdis\/jix503","article-title":"An adjuvanted, post-fusion F protein-based vaccine did not prevent respiratory syncytial virus illness in older adults","volume":"216","author":"Falloon","year":"2017","journal-title":"J. Infect. Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"8143","DOI":"10.1038\/ncomms9143","article-title":"A highly stable prefusion RSV F vaccine derived from structural analysis of the fusion mechanism","volume":"6","author":"Krarup","year":"2015","journal-title":"Nat. Commun."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1126\/science.1243283","article-title":"Structure-based design of a fusion glycoprotein vaccine for respiratory syncytial virus","volume":"342","author":"McLellan","year":"2013","journal-title":"Science"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Bose, M.E., He, J., Shrivastava, S., Nelson, M.I., Bera, J., Halpin, R.A., Town, C.D., Lorenzi, H.A., Noyola, D.E., and Falcone, V. (2015). Sequencing and analysis of globally obtained human respiratory syncytial virus A and B genomes. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0120098"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Vandini, S., Biagi, C., and Lanari, M. (2017). Respiratory Syncytial Virus: The Influence of Serotype and Genotype Variability on Clinical Course of Infection. Int. J. Mol. Sci., 18.","DOI":"10.3390\/ijms18081717"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.vaccine.2016.11.054","article-title":"Animal models of respiratory syncytial virus infection","volume":"35","author":"Taylor","year":"2017","journal-title":"Vaccine"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"eaaj1928","DOI":"10.1126\/scitranslmed.aaj1928","article-title":"A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants","volume":"9","author":"Zhu","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"305","DOI":"10.2165\/00003495-199958020-00009","article-title":"Palivizumab","volume":"58","author":"Scott","year":"1999","journal-title":"Drugs"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"294","DOI":"10.20411\/pai.v4i2.338","article-title":"Crystal structure and immunogenicity of the DS-Cav1-stabilized fusion glycoprotein from respiratory syncytial virus subtype b","volume":"4","author":"Joyce","year":"2019","journal-title":"Pathog. Immun."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Jones, H.G., Battles, M.B., Lin, C.C., Bianchi, S., Corti, D., and McLellan, J.S. (2019). Alternative conformations of a major antigenic site on RSV F. PLoS Pathog., 15.","DOI":"10.1371\/journal.ppat.1007944"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1038\/s41467-017-01858-w","article-title":"Structural basis of respiratory syncytial virus subtype-dependent neutralization by an antibody targeting the fusion glycoprotein","volume":"8","author":"Tian","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"e4400","DOI":"10.1093\/cid\/ciaa951","article-title":"Suptavumab for the prevention of medically attended respiratory syncytial virus infection in preterm infants","volume":"73","author":"Simoes","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1126\/science.aav9033","article-title":"A proof of concept for structure-based vaccine design targeting RSV in humans","volume":"365","author":"Crank","year":"2019","journal-title":"Science"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1016\/j.vaccine.2021.12.043","article-title":"Immunogenicity and protective efficacy of adenoviral and subunit RSV vaccines based on stabilized prefusion F protein in pre-clinical models","volume":"40","author":"Saeland","year":"2021","journal-title":"Vaccine"},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Saeland, E., van der Fits, L., Bolder, R., Heemskerk-van der Meer, M., Drijver, J., van Polanen, Y., Vaneman, C., Tettero, L., Cox, F., and Serroyen, J. (2022). Combination Ad26.RSV.preF\/RSV preF protein vaccine induces superior humoral, cellular, and protective immunity compared with individual vaccine components in preclinical models. bioRxiv.","DOI":"10.1101\/2022.09.23.509196"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1093\/infdis\/jiab003","article-title":"Prevention of Respiratory Syncytial Virus Infection in Healthy Adults by a Single Immunization of Ad26.RSV.preF in a Human Challenge Study","volume":"226","author":"Sadoff","year":"2021","journal-title":"J. Infect. Dis."},{"key":"ref_25","first-page":"1","article-title":"Clinical and biological consequences of respiratory syncytial virus genetic diversity","volume":"9","author":"Hultquist","year":"2022","journal-title":"Ther. Adv. Infect. Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"12941","DOI":"10.1038\/s41598-021-92435-1","article-title":"Genetic diversity and molecular evolution of human respiratory syncytial virus A and B","volume":"11","author":"Yu","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"5125","DOI":"10.1038\/s41467-021-25265-4","article-title":"Distinct patterns of within-host virus populations between two subgroups of human respiratory syncytial virus","volume":"12","author":"Lin","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1093\/infdis\/jiy189","article-title":"Prevalence and significance of substitutions in the fusion protein of respiratory syncytial virus resulting in neutralization escape from antibody MEDI8897","volume":"218","author":"Zhu","year":"2018","journal-title":"J. Infect. Dis."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.cell.2019.11.032","article-title":"Restricted clonality and limited germinal center reentry characterize memory b cell reactivation by boosting","volume":"180","author":"Mesin","year":"2020","journal-title":"Cell"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"a038786","DOI":"10.1101\/cshperspect.a038786","article-title":"Original antigenic sin: How original? how sinful?","volume":"11","author":"Yewdell","year":"2021","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"eabq5901","DOI":"10.1126\/sciimmunol.abq5901","article-title":"Immune memory to SARS-CoV-2 Omicron BA.1 breakthrough infections: To change the vaccine or not?","volume":"7","year":"2022","journal-title":"Sci. Immunol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1556","DOI":"10.1016\/j.cell.2022.03.038","article-title":"mRNA-1273 or mRNA-Omicron boost in vaccinated macaques elicits similar B cell expansion, neutralizing responses, and protection from Omicron","volume":"185","author":"Gagne","year":"2022","journal-title":"Cell"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.vaccine.2021.01.045","article-title":"A prospective surveillance study on the kinetics of the humoral immune response to the respiratory syncytial virus fusion protein in adults in Houston, Texas","volume":"39","author":"Blunck","year":"2021","journal-title":"Vaccine"}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/11\/3\/672\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T18:56:28Z","timestamp":1760122588000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/11\/3\/672"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,16]]},"references-count":33,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,3]]}},"alternative-id":["vaccines11030672"],"URL":"https:\/\/doi.org\/10.3390\/vaccines11030672","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,16]]}}}